Breaking Down Revenue Trends: Eli Lilly and Company vs Bristol-Myers Squibb Company

Pharma Giants' Revenue Race: Eli Lilly vs. Bristol-Myers Squibb

__timestampBristol-Myers Squibb CompanyEli Lilly and Company
Wednesday, January 1, 20141587900000019615600000
Thursday, January 1, 20151656000000019958700000
Friday, January 1, 20161942700000021222100000
Sunday, January 1, 20172077600000022871300000
Monday, January 1, 20182256100000021493300000
Tuesday, January 1, 20192614500000022319500000
Wednesday, January 1, 20204251800000024539800000
Friday, January 1, 20214638500000028318400000
Saturday, January 1, 20224615900000028541400000
Sunday, January 1, 20234500600000034124100000
Monday, January 1, 20244830000000045042700000
Loading chart...

Infusing magic into the data realm

Revenue Trends: Eli Lilly vs. Bristol-Myers Squibb

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. Over the past decade, Eli Lilly and Bristol-Myers Squibb have demonstrated distinct revenue trajectories. From 2014 to 2023, Bristol-Myers Squibb's revenue surged by approximately 184%, peaking in 2021 with a 46% increase from the previous year. Meanwhile, Eli Lilly experienced a steady growth of around 74% over the same period, with a notable 20% rise in 2023. This divergence highlights Bristol-Myers Squibb's aggressive expansion strategy, particularly evident in the 2020-2021 period, while Eli Lilly's consistent growth underscores its stable market presence. As these pharmaceutical giants continue to innovate and expand, their revenue trends offer valuable insights into their strategic priorities and market dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025